study population (12.75%). Thus we can confirm that the presence of vaginal and cervical ulcers may be considered an additional risk factor for HIV transmission. Although our study was performed on sera belonging to women considered at risk for HIV infections, only 2% of them were certainly infected by HIV-1 and none was infected by HIV-2. This percentage is consistent with another study on an analogous sample of 100 women in February 1993 (data not shown).

During the last 10 years, the war in Angola has greatly limited movement of people between Luanda province and the bordering provinces of Congo, Zaire and Zambia. Probably the low prevalence of HIV in Luanda is due to the partial isolation of the city during the spread of HIV pandemic in Sub Sahara Africa.

This work was funded by MURST and DDCC-MAE, Italy (National Laboratory of Public Health, Luanda-programme) and by Ministry of Health, Republic of Angola, AIDS control programme. We are grateful to Dr Antonia Hembe, the director and the medical team of Luercia Pain Hospital of Luanda and to Dr A Bortolan and Dr G Riva for their helpful collaboration.

P PORTINCASA
T ZANNINO
G DETTORI
C CHEZZI
Istituto di Microbiologia,
Università degli Studi di Parma, Italy
N DOS SANTOS
Laboratorio Nazionale Salute Publica,
Luanda, Angola
M VANDUNEN
Maternidade Luercia Pain,
Luanda, Angola
C LEMOS
World Health Organization,
Luanda, Angola
S RUBINO
P CAPPUCCINELLI
Istituto di Microbiologia e Virologia,
Università degli Studi di Sassari, Italy
M M COLOMBO
Dipartimento di Biologia Cellulare e dello Sviluppo,
Università La Sapienza, Roma, Italy

Correspondence to: Dr Piero Cappuccinelli, Istituto di Microbiologia e Virologia, Viale San Pietro 43B, 07100 Sassari, Italy.

Anaphylaxis due to liposomal amphotericin (AmBisome)

As patients with AIDS are living longer, increasing numbers are developing systemic infections with Cryptococcus neoformans necessitating intravenous amphotericin therapy.

Liposomal amphotericin B (AmBisome) is a recently introduced preparation and is claimed to be less commonly associated with adverse effects than conventional amphotericin B. It is therefore a reasonable alternative to use in patients with systemic fungal infection where conventional amphotericin B has been previously associated with renal toxicity.

Two cases of anaphylaxis due to liposomal amphotericin in patients who were not allergic to amphotericin B have recently been described.2 We report a further case of anaphylaxis occurring in a patient being given his first injection of AmBisome for treatment of cryptococcal meningitis.

A 28 year old male patient who had been diagnosed HIV positive 9 years previously was admitted with a week's history of headache, photophobia and vomiting. Cryptococcal meningitis had been successfully treated 9 months previously with conventional intravenous amphotericin B. Subsequently, the patient was maintained on fluconazole but relapsed six months later. Initially, this was treated with intravenous amphotericin B. However, signs of renal toxicity, as shown by rising creatinine and urea, developed after two days and fluconazole was substituted. The patient recovered and again was maintained on fluconazole. After a further month this was changed to itraconazole because of nausea due to fluconazole.

On admission, medication included dapsone 50mg daily, pyrimethamine 50mg weekly, and itraconazole 400mg daily. CT of the brain was normal and examination of CSF showed 22 white blood cells/mm³ (the majority were lymphocytes) and two yeast cells. Both CSF and serum were positive for cryptococcal antigen. Relapse of cryptococcal meningitis was diagnosed and intravenous liposomal amphotericin B (AmBisome) at a dose of 1 mg/kg was commenced. Within seconds of starting the infusion the patient vomited and complained of epigastric pain and abdominal tightness. Bronchospasm, facial flushing and sweating were noted. The infusion was immediately discontinued and symptoms settled within 4 hours. Subsequent treatment comprised of flucytosine and itraconazole and the patient made an uneventful recovery.

It is well recognised that HIV positive patients have a higher incidence of adverse drug reactions compared with the general population and these cases further highlight the need for care to be taken when giving medication to this group of patients.

C M BATES
P B CAREY
Department of Genitoourinary Medicine
C R K HIND
Department of Medicine
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Liverpool L7 8XP, UK

Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarin induction therapy

Foscarin (Foscavir, Astra Pharmaceuticals) has been used for the treatment of
Anaphylaxis due to liposomal amphotericin (AmBisome)

C M Bates, P B Carey and C R Hind

Genitourin Med 1995 71: 414
doi: 10.1136/sti.71.6.414

Updated information and services can be found at:
http://sti.bmj.com/content/71/6/414.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/